Annual EBITDA
$90.04 M
-$63.31 M-41.28%
31 December 2023
Summary:
Supernus Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $90.04 million, with the most recent change of -$63.31 million (-41.28%) on 31 December 2023. During the last 3 years, it has fallen by -$120.50 million (-57.23%). SUPN annual EBITDA is now -57.23% below its all-time high of $210.54 million, reached on 31 December 2020.SUPN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$65.05 M
+$18.02 M+38.33%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $65.05 million, with the most recent change of +$18.02 million (+38.33%) on 30 September 2024. Over the past year, it has increased by +$33.30 million (+104.89%). SUPN quarterly EBITDA is now -2.40% below its all-time high of $66.64 million, reached on 30 September 2020.SUPN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$155.72 M
+$33.30 M+27.20%
30 September 2024
Summary:
Supernus Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $155.72 million, with the most recent change of +$33.30 million (+27.20%) on 30 September 2024. Over the past year, it has increased by +$30.76 million (+24.62%). SUPN TTM EBITDA is now -26.17% below its all-time high of $210.91 million, reached on 31 December 2020.SUPN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -41.3% | +104.9% | +24.6% |
| 3 y3 years | -57.2% | +56.5% | -2.8% |
| 5 y5 years | -45.5% | +38.6% | -10.8% |
SUPN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -57.2% | at low | at high | +1342.9% | -2.8% | +94.9% |
| 5 y | 5 years | -57.2% | at low | -2.4% | +1342.9% | -26.2% | +94.9% |
| alltime | all time | -57.2% | +207.6% | -2.4% | +359.7% | -26.2% | +286.1% |
Supernus Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $65.05 M(+38.3%) | $155.72 M(+27.2%) |
| June 2024 | - | $47.02 M(+124.0%) | $122.42 M(+53.2%) |
| Mar 2024 | - | $20.99 M(-7.4%) | $79.91 M(-11.3%) |
| Dec 2023 | $90.04 M(-41.3%) | $22.67 M(-28.6%) | $90.04 M(-27.9%) |
| Sept 2023 | - | $31.75 M(+604.2%) | $124.96 M(+7.5%) |
| June 2023 | - | $4.51 M(-85.5%) | $116.27 M(-20.6%) |
| Mar 2023 | - | $31.12 M(-46.0%) | $146.45 M(-4.5%) |
| Dec 2022 | $153.36 M(+18.7%) | $57.58 M(+149.8%) | $153.36 M(+31.7%) |
| Sept 2022 | - | $23.05 M(-33.5%) | $116.47 M(-13.7%) |
| June 2022 | - | $34.69 M(-8.8%) | $134.97 M(-6.0%) |
| Mar 2022 | - | $38.03 M(+83.8%) | $143.60 M(+11.2%) |
| Dec 2021 | $129.19 M(-38.6%) | $20.69 M(-50.2%) | $129.19 M(-19.3%) |
| Sept 2021 | - | $41.56 M(-4.1%) | $160.18 M(-13.5%) |
| June 2021 | - | $43.32 M(+83.4%) | $185.26 M(-6.4%) |
| Mar 2021 | - | $23.62 M(-54.3%) | $198.01 M(-6.1%) |
| Dec 2020 | $210.54 M(+19.0%) | $51.68 M(-22.5%) | $210.91 M(+1.6%) |
| Sept 2020 | - | $66.64 M(+18.9%) | $207.55 M(+10.5%) |
| June 2020 | - | $56.07 M(+53.5%) | $187.84 M(+3.4%) |
| Mar 2020 | - | $36.52 M(-24.4%) | $181.58 M(+2.7%) |
| Dec 2019 | $176.85 M(+7.0%) | $48.32 M(+3.0%) | $176.84 M(+1.3%) |
| Sept 2019 | - | $46.93 M(-5.8%) | $174.58 M(+1.8%) |
| June 2019 | - | $49.81 M(+56.7%) | $171.48 M(+5.3%) |
| Mar 2019 | - | $31.79 M(-31.0%) | $162.83 M(-1.5%) |
| Dec 2018 | $165.35 M(+49.9%) | $46.06 M(+5.1%) | $165.35 M(+5.9%) |
| Sept 2018 | - | $43.82 M(+6.5%) | $156.17 M(+11.7%) |
| June 2018 | - | $41.16 M(+20.0%) | $139.79 M(+10.4%) |
| Mar 2018 | - | $34.31 M(-7.0%) | $126.61 M(+14.8%) |
| Dec 2017 | $110.32 M | $36.88 M(+34.4%) | $110.32 M(+21.7%) |
| Sept 2017 | - | $27.44 M(-1.9%) | $90.61 M(+7.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2017 | - | $27.99 M(+55.4%) | $84.13 M(+22.0%) |
| Mar 2017 | - | $18.01 M(+4.9%) | $68.96 M(+19.2%) |
| Dec 2016 | $57.86 M(+185.0%) | $17.17 M(-18.0%) | $57.86 M(+17.5%) |
| Sept 2016 | - | $20.95 M(+63.4%) | $49.26 M(+45.4%) |
| June 2016 | - | $12.82 M(+85.5%) | $33.87 M(+35.3%) |
| Mar 2016 | - | $6.91 M(-19.4%) | $25.03 M(+23.3%) |
| Dec 2015 | $20.30 M(-641.9%) | $8.57 M(+53.9%) | $20.30 M(+13.4%) |
| Sept 2015 | - | $5.57 M(+39.8%) | $17.89 M(+51.5%) |
| June 2015 | - | $3.98 M(+82.9%) | $11.81 M(-5.8%) |
| Mar 2015 | - | $2.18 M(-64.7%) | $12.54 M(-434.9%) |
| Dec 2014 | -$3.75 M(-95.5%) | $6.17 M(-1297.3%) | -$3.75 M(-87.5%) |
| Sept 2014 | - | -$515.00 K(-110.9%) | -$29.99 M(-40.6%) |
| June 2014 | - | $4.71 M(-133.4%) | -$50.51 M(-37.1%) |
| Mar 2014 | - | -$14.11 M(-29.7%) | -$80.27 M(-4.1%) |
| Dec 2013 | -$83.68 M(+100.0%) | -$20.08 M(-4.5%) | -$83.68 M(+10.0%) |
| Sept 2013 | - | -$21.03 M(-16.1%) | -$76.09 M(+12.8%) |
| June 2013 | - | -$25.05 M(+42.9%) | -$67.45 M(+31.6%) |
| Mar 2013 | - | -$17.52 M(+40.3%) | -$51.27 M(+22.6%) |
| Dec 2012 | -$41.84 M(+13.9%) | -$12.49 M(+0.8%) | -$41.84 M(+6.7%) |
| Sept 2012 | - | -$12.39 M(+39.7%) | -$39.22 M(+7.4%) |
| June 2012 | - | -$8.87 M(+9.7%) | -$36.52 M(+1.9%) |
| Mar 2012 | - | -$8.09 M(-18.0%) | -$35.83 M(-2.9%) |
| Dec 2011 | -$36.73 M(-4.1%) | -$9.87 M(+1.8%) | -$36.88 M(-20.0%) |
| Sept 2011 | - | -$9.69 M(+18.5%) | -$46.13 M(+26.6%) |
| June 2011 | - | -$8.18 M(-10.6%) | -$36.44 M(+28.9%) |
| Mar 2011 | - | -$9.15 M(-52.2%) | -$28.26 M(+47.8%) |
| Dec 2010 | -$38.29 M(-834.9%) | -$19.12 M(+42.3%) | -$19.12 M(+42.3%) |
| Dec 2009 | $5.21 M(-122.0%) | -$13.44 M | -$13.44 M |
| Dec 2008 | -$23.69 M(+45.0%) | - | - |
| Dec 2007 | -$16.34 M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual EBITDA year-on-year change?
- What is Supernus Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Supernus Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM EBITDA year-on-year change?
What is Supernus Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SUPN is $90.04 M
What is the all time high annual EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $210.54 M
What is Supernus Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, SUPN annual earnings before interest, taxes, depreciation & amortization has changed by -$63.31 M (-41.28%)
What is Supernus Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SUPN is $65.05 M
What is the all time high quarterly EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $66.64 M
What is Supernus Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SUPN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$33.30 M (+104.89%)
What is Supernus Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SUPN is $155.72 M
What is the all time high TTM EBITDA for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $210.91 M
What is Supernus Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SUPN TTM earnings before interest, taxes, depreciation & amortization has changed by +$30.76 M (+24.62%)